Cardiopulmonary Responses to 6-Minute Stepper Test in Bronchiectasis Versus Healthy Controls
Comparison of Cardiopulmonary Responses to 6-Minute Stepper Test Between Individuals With Bronchiectasis and Healthy Controls
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Aslihan Cakmak-Onal Study Principal Investigator, PhD, PT
- Phone Number: +903123051576
- Email: aslihancakmak90@gmail.com
Study Contact Backup
- Name: Elif Kocaaga, MSc, PT
Study Locations
-
-
-
Ankara, Turkey (Türkiye), 06100
- Recruiting
- Hacettepe University Faculty of Physical Therapy and Rehabilitation
-
Principal Investigator:
- Aslihan Cakmak-Onal, PhD, PT
-
Sub-Investigator:
- Elif Kocaaga, MSc, PT
-
Sub-Investigator:
- Deniz Inal-Ince, PhD, PT
-
Contact:
- Elif Kocaaga, MSc, PT
-
Contact:
- Aslihan Cakmak-Onal, PhD, PT
- Phone Number: +903123051576
- Email: aslihancakmak90@gmail.com
-
Sub-Investigator:
- Naciye Vardar-Yagli, PhD, PT
-
Sub-Investigator:
- Ziya Toros Selcuk, MD
-
Sub-Investigator:
- Melda Saglam, PhD, PT
-
Sub-Investigator:
- Ebru Calik-Kutukcu, PhD, PT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Bronchiectasis group - Inclusion criteria for the study:
- Being 18 years of age and older,
- Having a clinically stable bronchiectasis,
- To cooperate with the tests to be performed,
- Not having a cardiovascular disease, orthopedic or neurological problem that may affect the tests,
- Being willing to participate in the study.
Bronchiectasis group - Exclusion criteria:
- Being in an acute exacerbation period,
- Having a cardiovascular, orthopedic or neurological problem that may affect the tests,
- Not being willing to participate in the study.
Control group - Inclusion criteria for the study:
- Being 18 years of age and older,
- To cooperate with the tests to be performed,
- Not having a cardiovascular, orthopedic or neurological problem that may affect the tests,
- Being willing to participate in the study.
Control group - Exclusion criteria:
- Individuals with any known internal disease and those who do not volunteer to participate in the study will not be included in the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy controls
|
No intervention
|
|
Bronchiectasis
Individuals with bronchiectasis
|
No intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal inspiratory pressure
Time Frame: 1st day
|
Maximal inspiratory pressure (MIP) and will be measured using aa mouth-piece pressure measurement device.
The measurement will be repeated three times so that there will be no difference of 10 cmH₂O or 10%, and the highest value will be used for analysis.
|
1st day
|
|
Maximal expiratory pressure
Time Frame: 1st day
|
Maximal expiratory pressure (MEP) and will be measured using a mouth-piece pressure measurement device.
The measurement will be repeated three times so that there will be no difference of 10 cmH₂O or 10%, and the highest value will be used for analysis.
|
1st day
|
|
Peripheral muscle strength
Time Frame: 1st day
|
Peripheral muscle strength will be assessed using a portable dynamometer.
The peripheral muscle strength test will be repeated three times for the right and left sides.
|
1st day
|
|
6-minute stepper test responses
Time Frame: 1st day
|
6-minute stepper test will be performed, and the number of repetitions will be recorded.
Cardiopulmonary responses before and after 6-minute stepper test will be recorded.
6-minute stepper test will be performed twice with 30 minutes apart.
|
1st day
|
|
1 minute sit-to-stand test responses
Time Frame: 1 minute sit-to-stand test will be performed and the repetitions will be recoded. Cardiopulmonary responses will be recorded before and after the test.
|
1 minute sit-to-stand test will be performed and the repetitions will be recoded.
Cardiopulmonary responses will be recorded before and after the test.
|
1 minute sit-to-stand test will be performed and the repetitions will be recoded. Cardiopulmonary responses will be recorded before and after the test.
|
|
6-minute walk test responses
Time Frame: 1st day
|
6-minute walk test will be performed, and the distance walked will be recorded.
Cardiopulmonary responses before and after 6-minute walk test will be recorded.
|
1st day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced vital capacity
Time Frame: 1st day
|
Pulmonary function test using a spirometer will be performed.
Forced vital capacity will be recorded.
|
1st day
|
|
Forced expiratory volume in one second
Time Frame: 1st day
|
Pulmonary function test using a spirometer will be performed.
Forced expiratory volume in one second will be recorded.
|
1st day
|
|
Peak expiratory flow
Time Frame: 1st day
|
Pulmonary function test using a spirometer will be performed.
Peak expiratory flow will be recorded.
|
1st day
|
|
Forced mid-expiratory flow (FEF25-75)
Time Frame: 1st day
|
Pulmonary function test using a spirometer will be performed.
Forced mid-expiratory flow (FEF25-75) will be recorded.
|
1st day
|
|
Dyspnea
Time Frame: 1st day
|
The modified Medical Research Council (mMRC) dyspnea scale will be used for dyspnea assessment.
The mMRC dyspnea scale is a scale in which individuals choose the expression that best describes their dyspnea level from among 5 expressions related to shortness of breath.
The higher the degree, the more severe the shortness of breath.
|
1st day
|
|
Charlson Comorbidity Index
Time Frame: 1st day
|
Charlson Comorbidity Index (CCI) will be used to query accompanying comorbidities.
Higher CCI scores indicate a greater burden of comorbid conditions.
|
1st day
|
|
Bronchiectasis Severity Index
Time Frame: 1st day
|
Bronchiectasis Severity Index will be used to evaluate disease severity and prognosis in bronchiectasis.
It is calculated by respiratory function, age, chronic colonization with Pseudomonas aeruginosa and other bacterial infections, shortness of breath and radiological extent of the disease.
Based on Bronchiectasis Severity Index, bronchiectasis severity is defined as mild (0-4), moderate (5-8) and severe (≥9).
|
1st day
|
|
Forced expiratory volume in one second/forced vital capacity ratio
Time Frame: 1st day
|
Pulmonary function test using a spirometer will be performed.
Forced expiratory volume in one second/forced vital capacity ratio will be recorded.
|
1st day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SBA 24/793
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.